29,249 Shares in MeiraGTx Holdings plc (NASDAQ:MGTX) Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC purchased a new position in MeiraGTx Holdings plc (NASDAQ:MGTX) during the second quarter, Holdings Channel reports. The fund purchased 29,249 shares of the company’s stock, valued at approximately $123,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its holdings in shares of MeiraGTx by 14.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock worth $1,949,000 after buying an additional 58,854 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of MeiraGTx by 3.7% in the 1st quarter. Vanguard Group Inc. now owns 323,891 shares of the company’s stock worth $1,966,000 after buying an additional 11,470 shares during the last quarter. Privium Fund Management B.V. raised its stake in MeiraGTx by 70.0% in the 2nd quarter. Privium Fund Management B.V. now owns 203,960 shares of the company’s stock valued at $804,000 after acquiring an additional 83,975 shares during the period. Russell Investments Group Ltd. raised its stake in MeiraGTx by 1.9% in the 1st quarter. Russell Investments Group Ltd. now owns 157,999 shares of the company’s stock valued at $959,000 after acquiring an additional 2,994 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in MeiraGTx in the 1st quarter valued at about $706,000. 67.48% of the stock is owned by hedge funds and other institutional investors.

MeiraGTx Trading Up 5.5 %

Shares of MeiraGTx stock opened at $4.25 on Monday. The stock’s 50-day simple moving average is $4.16 and its 200 day simple moving average is $4.66. MeiraGTx Holdings plc has a 52-week low of $3.49 and a 52-week high of $7.60. The stock has a market capitalization of $273.30 million, a P/E ratio of -3.63 and a beta of 1.29. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.36 and a current ratio of 2.36.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.45). MeiraGTx had a negative net margin of 1,146.81% and a negative return on equity of 152.82%. The company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $16.38 million. As a group, research analysts anticipate that MeiraGTx Holdings plc will post -1.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MGTX shares. Royal Bank of Canada lowered their price objective on MeiraGTx from $11.00 to $9.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Chardan Capital restated a “buy” rating and issued a $36.00 price objective on shares of MeiraGTx in a research note on Wednesday, July 31st.

Insider Activity

In related news, Director Perceptive Advisors Llc purchased 1,250,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were purchased at an average cost of $4.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director now directly owns 12,531,103 shares in the company, valued at approximately $50,124,412. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 8.40% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.